Скачать или смотреть New business models for Big Pharma

This situation has a big impact on the big pharmaceutical blockbuster business model, which is based on top selling drugs that generated over 1 billion USD in annual sales. Large pharmaceutical companies are changing and adapting their capabilities by focusing on external growth, more precisely mergers and acquisitions (M&A), to increase R&D capabilities and boost portfolio with biotech companies as preferred targets.

In the past 10 years, merger and acquisition activities have significantly increased, with a high in 2015 when the total value reached more than 345 billion USD. 2019 started with the same strength, a mega merger between Bristol-Myers Squibb and Celgene of 95 billion USD (including debt recovery)—an astronomical amount which confirms the growing interest in biotech.